Search Result

Results for "

GSK3-IN-3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GSK-3 (71) AAK1 (1) Angiotensin Receptor (1) Apoptosis (10) Aryl Hydrocarbon Receptor (1) Autophagy (10) c-Myc (1) Calcium Channel (2) CDK (21) CFTR (1) Cholinesterase (ChE) (1) DYRK (2) ERK (2) FGFR (1) HIV (1) HSV (3) Integrin (1) JAK (2) JNK (1) LIM Kinase (LIMK) (1) Lipoxygenase (1) MAP3K (1) MEK (2) Mitophagy (1) Organoid (3) Parasite (2) Pim (1) PKC (2) PROTACs (1) Proton Pump (2) RANKL/RANK (1) Ribosomal S6 Kinase (RSK) (1) Src (1) Tau Protein (3) Wnt (4) β-catenin (5)
By Research Areas:	Cancer (39) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (8) Metabolic Disease (16) Neurological Disease (31)

By Targets:

GSK-3 (71)

AAK1 (1)

Angiotensin Receptor (1)

Apoptosis (10)

Aryl Hydrocarbon Receptor (1)

Autophagy (10)

c-Myc (1)

Calcium Channel (2)

CDK (21)

CFTR (1)

Cholinesterase (ChE) (1)

DYRK (2)

ERK (2)

FGFR (1)

HIV (1)

HSV (3)

Integrin (1)

JAK (2)

JNK (1)

LIM Kinase (LIMK) (1)

Lipoxygenase (1)

MAP3K (1)

MEK (2)

Mitophagy (1)

Organoid (3)

Parasite (2)

Pim (1)

PKC (2)

PROTACs (1)

Proton Pump (2)

RANKL/RANK (1)

Ribosomal S6 Kinase (RSK) (1)

Src (1)

Tau Protein (3)

Wnt (4)

β-catenin (5)

By Research Areas:

Cancer (39)

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (8)

Metabolic Disease (16)

Neurological Disease (31)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: GSK-3 AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-153089

*GSK3-IN-3* 1 Publications Verification	GSK-3 Mitophagy	Neurological Disease
GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a *GSK-3* inhibitor with an IC₅₀ value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA .

HY-130795

GSK-3β inhibitor 2 1 Publications Verification	GSK-3	Neurological Disease
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active *GSK-3β* inhibitor with an IC₅₀ of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .

HY-148133

GSK-3β inhibitor 12	GSK-3	Neurological Disease
GSK-3β inhibitor 12 (compound 15) is an inhibitor of *GSK-3β. GSK-3β inhibitor 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3*β inhibitor 12 can be used for the research of neurodegenerative diseases .

HY-149054

GSK-3β inhibitor 13	GSK-3 Tau Protein AAK1 Pim PKC	Neurological Disease
GSK-3β inhibitor 13 (compound 47) is an orally active and potent *GSK-3β* inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits *GSK-3β* and *GSK-3α* with IC₅₀s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC₅₀=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease .

HY-149542

GSK-3β inhibitor 15	Tau Protein Apoptosis GSK-3	Neurological Disease
GSK-3β inhibitor 15 (Compound 54) is a *GSK-3β* inhibitor (IC₅₀: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ_1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ_1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .

HY-15438

SB 415286 5+ Cited Publications	GSK-3 Apoptosis	Metabolic Disease
SB 415286 is a potent and selective cell permeable inhibitor of *GSK-3α, with an IC₅₀* of 77.5 nM, and a K_i of 30.75 nM; SB 415286 is equally effective at inhibiting human *GSK-3α* and *GSK-3β*.

HY-143261

GSK-3β inhibitor 7	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 7 is a *GSK-3β* inhibitor with an IC₅₀ value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-154851

*GSK-3 inhibitor 3*	GSK-3 CDK Tau Protein	Neurological Disease
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of *GSK-3, with IC₅₀s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3* lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC₅₀ of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research .

HY-147134

GSK-3β inhibitor 10	GSK-3	Neurological Disease
GSK-3β inhibitor 10 (compound 14a) is a highly potent *GSK-3β* inhibitor with an IC₅₀ value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease .

HY-149845

PROTAC GSK-3β Degrader-1	GSK-3 PROTACs	Neurological Disease
PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targets *GSK-3β* degradation with an IC₅₀ value of 833 nM. PROTAC GSK-3β Degrader-1 contains SB-216763 (a GSK-3β inhibitor), a PEG linker and a CRBN (E3 ligase liand). PROTAC GSK-3β Degrader-1 reduces the neurotoxicity induced by Aβ_25-35 peptide and CuSO₄. PROTAC GSK-3β Degrader-1 can be used to research in Alzheimer's disease .

HY-143260

GSK-3β inhibitor 6	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 6 is a potent *GSK-3β* inhibitor with an IC₅₀ value of 24.4 μM. GSK-3β inhibitor 6 shows high hepatocyte glucose uptake (38%). GSK-3β inhibitor 6 can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-120902

GSK-3β inhibitor 8	GSK-3	Inflammation/Immunology
GSK-3β inhibitor 8, a thiophenacil derivative, is an effective and selective inhibitor of *GSK-3β* (IC₅₀=64 nM). GSK-3β inhibitor 8 negatively regulated Wnt signaling pathway and stimulated β cell proliferation .

HY-141480

GSK-3β inhibitor 3	GSK-3 Apoptosis	Cancer
GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC₅₀ of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia .

HY-148132

GSK-3β inhibitor 11	GSK-3	Neurological Disease
GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC₅₀=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .

HY-153760

GSK-3β inhibitor 14

GSK-3 Neurological Disease Metabolic Disease

GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak GSK-3β inhibitor (IC₅₀ >100 μM) .

GSK-3β inhibitor 14	GSK-3	Neurological Disease Metabolic Disease
GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak *GSK-3β* inhibitor (IC₅₀ >100 μM) .

HY-12012

SB 216763 25+ Cited Publications	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 is potent, selective and ATP-competitive *GSK-3* inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

HY-126144

GSK-3β inhibitor 1 2 Publications Verification	GSK-3	Metabolic Disease
GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM .

HY-16294

LY2090314 10+ Cited Publications	GSK-3	Cancer
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

HY-15761

AZD2858 5+ Cited Publications	GSK-3	Neurological Disease
AZD2858 is a potent, orally active *GSK-3* inhibitor, with IC₅₀s of 0.9 and 5 nM for *GSK-3α* and *GSK-3β*, respectively, used in the research of fracture healing.

HY-14872

Tideglusib 5 Publications Verification NP031112	GSK-3	Neurological Disease
Tideglusib (NP031112) is an irreversible *GSK-3* inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β ^WT (1 h preincubation) and GSK-3β ^C199A (1 h preincubation), respectively.

HY-111055

BIP-135	GSK-3	Neurological Disease
BIP-135 is a potent and selective ATP-competitive *GSK-3* inhibitor, with IC₅₀s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect .

HY-13076

CHIR-98014 3 Publications Verification	GSK-3	Metabolic Disease
CHIR-98014 is a potent, cell-permeable *GSK-3* inhibitor with IC₅₀s of 0.65 and 0.58 nM for *GSK-3α* and *GSK-3β*, respectively; it shows less potent activities against cdc2 and erk2.

HY-12292

IM-12

5 Publications Verification

GSK-3 Cancer

IM-12 is an inhibitor of GSK-3β, with an IC₅₀ of 53 nM, and also enhances Wnt signalling.

IM-12 5 Publications Verification	GSK-3	Cancer
IM-12 is an inhibitor of *GSK-3β, with an IC₅₀* of 53 nM, and also enhances Wnt signalling.

HY-107531

A 1070722	GSK-3	Cancer
A 1070722 is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor, with a K_i of 0.6 nM for both GSK-3α and GSK-3β. A 1070722 can penetrate the blood-brain barrier (BBB) and accumulates in brain regions, thus potential for PET radiotracer for the quantification of GSK-3 in brain .

HY-10590

TWS119 20+ Cited Publications	GSK-3 Autophagy	Neurological Disease Cancer
TWS119 is a specific inhibitor of *GSK-3β, with an IC₅₀* of 30 nM, and activates the wnt/β-catenin pathway.

HY-117194

18BIOder

HIV GSK-3 Infection

18BIOder is a neuroprotective GSK-3β inhibitor, highly selectively inhibiting HIV-1 .

18BIOder	HIV GSK-3	Infection
18BIOder is a neuroprotective *GSK-3β inhibitor, highly selectively inhibiting HIV*-1 .

HY-122026

PF-04802367 PF-367	GSK-3	Neurological Disease
PF-04802367 (PF-367) is a highly selective *GSK-3* inhibitor with an IC₅₀ of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and *GSK-3β) with IC₅₀* values of 10.0 and 9.0 nM in mobility shift assays, respectively .

HY-110074

TWS119 TFA

Others Others

TWS119 TFA is a specific inhibitor of GSK-3β, with an IC₅₀ of 30 nM, and activates the wnt/β-catenin pathway.

TWS119 TFA	Others	Others
TWS119 TFA is a specific inhibitor of *GSK-3β, with an IC₅₀* of 30 nM, and activates the wnt/β-catenin pathway.

HY-144826

ZDWX-25	GSK-3	Neurological Disease
ZDWX-25 is a highly potent *GSK-3β* and DYRK1A dual inhibitor with an IC₅₀ value of 71 nM for GSK-3β. ZDWX-25 possesses significant cytotoxic activities against SH-SY5Y and HL-7702 cells. ZDWX-25 can be used for researching alzheimer's disease .

HY-12524

Bikinin 1 Publications Verification AbrasIN	GSK-3	Others
Bikinin is a non-steroidal, ATP-competitive inhibitor of plant GSK-3/Shaggy-like kinases and activates BR (brassinosteroids) signaling.

HY-B0320A

Cromolyn sodium 3 Publications Verification Disodium Cromoglycate; FPL-670	Calcium Channel GSK-3	Inflammation/Immunology
Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic agent. Cromolyn sodium is a *GSK-3β* inhibitor with an IC₅₀ of 2.0 μM.

HY-144290

ARN25068

GSK-3 DYRK Neurological Disease

ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .

ARN25068	GSK-3 DYRK	Neurological Disease
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .

HY-119940

MC180295 (rel)-MC180295	CDK	Cancer
MC180295 ((rel)-MC180295) is a potent and selective CDK9-Cyclin T1 inhibitor, with an IC₅₀ of 5 nM, at least 22-fold more selective for CDK9 over other CDKs. MC180295 also inhibits GSK-3α and GSK-3β. MC180295 ((rel)-MC180295) has potent anti-tumor effect .

HY-111379

EHT 5372	DYRK CDK GSK-3	Neurological Disease Metabolic Disease Cancer
EHT 5372 is a highly potent and selective inhibitor of DYRK's family kinases with IC₅₀s of 0.22, 0.28, 10.8, 93.2, 22.8, 88.8, 59.0, 7.44, and 221 nM for DYRK1A, DYRK1B, DYRK2, DYRK3, CLK1, CLK2, CLK4, GSK-3α, and GSK-3β, respectively .

HY-126144A

(E/Z)-GSK-3β inhibitor 1	GSK-3	Metabolic Disease
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM .

HY-144316

ZLWH-23	Cholinesterase (ChE) GSK-3	Neurological Disease
ZLWH-23 is a selective AChE inhibitor (IC₅₀=0.27 μM) with *GSK-3β* inhibitory property (IC₅₀=6.78 μM). ZLWH-23 possesses selectivity for AChE over BChE (IC₅₀=20.82 μM) and for GSK-3β over multi-kinases. ZLWH-23 has the potential for the research of Alzheimer's disease .

HY-107530

3F8	GSK-3	Cardiovascular Disease Metabolic Disease Cancer
3F8 is a potent and selective *GSK-3β* inhibitor that could be useful as new reagent and potential therapeutic candidate for GSK3 related diseases .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of *GSK-3, CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-148561

CDK8-IN-12	CDK GSK-3 PKC	Cancer
CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a K_i of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with K_is of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent .

HY-N0815

Resibufogenin 5+ Cited Publications BufogenIN; RecibufogenIN	Others	Cancer
Resibufogenin, a component of huachansu, has been shown to exhibit the anti-proliferative effect against cancer cells, and this may be attributed to the degradation of cyclin D1 caused by the activation of GSK-3β.

HY-59090

1-Azakenpaullone 3 Publications Verification 1-Akp	GSK-3	Neurological Disease Metabolic Disease
1-Azakenpaullone (1-Akp) is a highly selective and ATP-competitive inhibitor of glycogen synthase kinase-3 β (GSK-3β), with an IC₅₀ value of 18 nM .

HY-100207

CP21R7 4 Publications Verification CP21	GSK-3	Cancer
CP21R7 is potent *GSK-3β* inhibitor, with an IC₅₀ of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC₅₀ of 1900 nM.

HY-15356

BIO-acetoxime 1 Publications Verification BIA	GSK-3 Apoptosis HSV	Infection Neurological Disease Inflammation/Immunology
BIO-acetoxime (BIA) is a potent and selective *GSK-3* inhibitor, with IC₅₀s of both 10 nM for GSK-3α/β. BIO-acetoxime has anticonvulsant and anti-infection activity.

HY-111931

Indirubin-3'-monoxime-5-sulphonic acid	CDK GSK-3	Cancer
Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of CDK1, CDK5, and *GSK-3β* with IC₅₀s of 5 nM, 7 nM, and 80 nM, respectively .

HY-B0320AR

Cromolyn sodium (Standard) Disodium Cromoglycate (Standard); FPL-670 (Standard)	Calcium Channel GSK-3	Inflammation/Immunology
Cromolyn (sodium) (Standard) is the analytical standard of Cromolyn (sodium). This product is intended for research and analytical applications. Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic agent. Cromolyn sodium is a *GSK-3β* inhibitor with an IC₅₀ of 2.0 μM.

HY-103221

MeBIO	Aryl Hydrocarbon Receptor GSK-3 CDK	Others
MeBIO is a potent AhR (aryl hydrocarbon receptor) agonist, with IC₅₀ of 44 μM (GSK-3) and 55 μM (CDK1/cyclin B), respectively. MeBIO is inactive on GSK-3β .

HY-10182G

Laduviglusib CHIR-99021; CT99021	GSK-3 Wnt β-catenin Autophagy	Metabolic Disease Cancer
Laduviglusib (CHIR-99021) (GMP) is Laduviglusib (HY-10182) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Laduviglusib is a potent, orally active and selective GSK-3α/β inhibitor.

HY-11012

TDZD-8 5+ Cited Publications GSK-3β INhibitor I; NP 01139	GSK-3	Cancer
TDZD-8 is an inhibitor of *GSK-3β, with an IC₅₀* of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC₅₀s of >100 μM.

HY-10096

TCS2002	GSK-3	Neurological Disease
TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent *GSK-3β* inhibitor with the IC₅₀ of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .

HY-137472

SAR502250	GSK-3	Neurological Disease
SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of *GSK3, with an IC₅₀* of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks